Repligen (RGEN) Director Karen A. Dawes Sells 20,000 Shares of Stock

Repligen (NASDAQ:RGEN) Director Karen A. Dawes sold 20,000 shares of the stock in a transaction that occurred on Friday, May 11th. The shares were sold at an average price of $41.80, for a total transaction of $836,000.00. Following the completion of the transaction, the director now owns 114,957 shares in the company, valued at $4,805,202.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

RGEN stock opened at $41.79 on Wednesday. The company has a market capitalization of $1.84 billion, a PE ratio of 60.57, a PEG ratio of 2.80 and a beta of 0.83. Repligen has a twelve month low of $41.70 and a twelve month high of $42.15. The company has a debt-to-equity ratio of 0.17, a current ratio of 12.22 and a quick ratio of 10.25.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported $0.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.02. The business had revenue of $44.80 million during the quarter, compared to the consensus estimate of $43.88 million. Repligen had a return on equity of 6.06% and a net margin of 18.48%. The company’s revenue was up 46.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.15 earnings per share. sell-side analysts predict that Repligen will post 0.71 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Guggenheim Capital LLC lifted its holdings in shares of Repligen by 6.0% during the first quarter. Guggenheim Capital LLC now owns 46,553 shares of the biotechnology company’s stock worth $1,685,000 after purchasing an additional 2,635 shares during the period. Barclays PLC lifted its holdings in shares of Repligen by 133.2% during the first quarter. Barclays PLC now owns 13,915 shares of the biotechnology company’s stock worth $504,000 after purchasing an additional 7,949 shares during the period. Bayesian Capital Management LP acquired a new stake in shares of Repligen during the first quarter worth $228,000. UBS Group AG lifted its holdings in shares of Repligen by 441.7% during the first quarter. UBS Group AG now owns 58,930 shares of the biotechnology company’s stock worth $2,132,000 after purchasing an additional 48,051 shares during the period. Finally, Profund Advisors LLC lifted its holdings in shares of Repligen by 29.2% during the first quarter. Profund Advisors LLC now owns 7,174 shares of the biotechnology company’s stock worth $260,000 after purchasing an additional 1,620 shares during the period. 87.29% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have commented on RGEN. BidaskClub upgraded shares of Repligen from a “hold” rating to a “buy” rating in a research note on Monday. Zacks Investment Research raised Repligen from a “hold” rating to a “buy” rating and set a $42.00 price objective for the company in a report on Thursday, April 26th. Finally, TheStreet raised Repligen from a “c” rating to a “b-” rating in a report on Tuesday, March 13th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Repligen currently has a consensus rating of “Buy” and a consensus price target of $44.25.

About Repligen

Repligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor.

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit